Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Blessings to everyone. CRXM investment aside, I have lots to be thankful for. Take care and enjoy the holiday.
I tried to get confirmation from the SEC and CRXM whether CRXM's trading was part of that SEC investigation. The SEC would not confirm since the process is ongoing. CRXM management never responded. Big surprise.
Interesting To Note That TIPRANKS Rates Altitrade Partners As A 5 Star Financial Blogger.....Yes They Have Had Some Big Winners Over The Years.....CRXM Could Become One Of Them
Altitrade your calls are very bad and many people prob followed you on many calls. All your crappy picks are down over 80-90%, so you better keep it to yourself.
Nice!
Thanks for sharing link.
CRXM?
I remember Sabby was here……
“Notably, in Jun? 2023, th? SEC acknowl?dg?d th? p?rsist?nc? of nak?d short s?lling as ?vid?nc?d by charging an Inv?stm?nt Advis?r for orch?strating an "Abusiv? Nak?d Short S?lling Sch?m?."
“The Securities and Exchange Commission today charged investment adviser Sabby Management LLC and its managing partner, Hal D. Mintz, with fraud in connection with a long running scheme involving misrepresentations and violations of rules for short selling and order making, as well as other violative trading, that generated more than $2 million in illegal profits.”
https://investorturf.com/investors-calling-for-temporary-ban-on-short-selling-in-the-united-states-stock-market
This scam is never coming back. I have 5-10k shares left. What a waste of space on my brokerage. Takes up an entire line
Sarepta also works in the gene therapy world and is having major issues. I am curious if they would be interested in buying this...if there is really anything to buy?
Altitrade.....Good to hear....Also nice to know the CEO Chris Reinhard has skin in the game.....Over 15 years working to develop Generx and over $1,000,000 in his own cash invested in the company.....I truly believe shareholders will prevail
Altitrade since you have posted that you were looking to buy CRXM shares from some of your fellow shareholders I would assume you feel pretty confident that the company will be able to raise the necessary money to proceed with the PHASE 3 for Generx.....What makes you feel so confident?.....What do you honestly see for the future of CRXM. and what is your anticipated timeframe?.....I respect your groups experience and solid track record
Altitrade since you have posted that you were looking to buy CRXM shares from some of your fellow shareholders I would assume you feel pretty confident that the company will be able to raise the necessary money to proceed with the PHASE 3 for Generx.....What makes you feel so confident?.....What do you honestly see for the future of CRXM. and what is your anticipated timeframe?.....I respect your groups experience and solid track record
Money. Specifically, the funding of the Phase III clinical trial.
It makes no sense to go through the process of obtaining compliance with SEC Rule 15c2-11 without being able to move the company forward.
Altitrade, what do you think is holding them back from getting filings done to be current ?
After I wrote the message and took a look at the stock you mentioned, I realized that is most likely the point.
Thanks for response and maybe that day will be soon for CRXM.
No. It's just one example of how a small biotech company can see its fortunes change overnight with a breakthrough clinical study.
Is this somehow related to CRXM?
Thanks
Agree!!!!!.....Nostrum should be bought out of their majority ownership of CRXM by a top Biotech Company.....Generx is very valuable and a Phase 3 fast tracked drug candidate that is more than a decade in the making.....The word needs to spread regarding this opportunity
Other drug candidates are failing at this problem of Myocardial ischemia all the while this company doesn’t do shit with their golden ticket.
https://www.koreabiomed.com/news/articleView.html?idxno=22154
Is he even alive? He was fairly old, no?
I rec'd a quick response from Mr Maher at the SEC.
"Hello xxxxxxxxx, thank you for your emails. Unfortunately I cannot say anything about the case beyond what is in the SEC’s complaint and litigation release. Sincerely, Dan
Big help...
Back in June I reached out to Mr Reinhard as well as the SEC to confirm whether CRXM's trading was part of this or not. I don't guess it will come as a surprise I have not received a response. Thanks for reminding me. I resent a request to the SEC litagator.
Has anyone else had luck speaking to Mr Reinhard about this?
If I remember correctly Sabby was here.
https://www.sec.gov/news/press-release/2023-107
No change in my thoughts, or my position.
Any thoughts on where this is headed with CRXM/Generx platform?
No worries, you don’t know if you don’t ask
I did not ask him for details, but he told me you contacted him.
He was interested selling at Altitrade's offer price, which sounded too good to be true. No free cheese.
I’m interested, just not at full retail price.
I messaged you his contact info over two months ago. He didn't get any contact from you.
He did mention crazyflavor contacted and was interested in buying.
It was legitimate.
Nobody was interested, so I moved on and deployed that investment capital into other opportunities.
You snooze, you lose.
Odds are whomever had the shares didn't want to sign a NDA and deal with whatever due diligence Altitrade would have expected. I imagine it would be a pain in the butt to get the shares transferred as well and take some time.
I would be surprised/disappointed if Altitrade's offer wasn't legit. He seems like an above board kind of guy.
On the other hand, one does have to wonder what the heck is going on with this company. You hear anything?
What offer are you referring to.....I am very confident Altitrade's was legitimate
Unfortunate that offer was fake, but had suspected as much. Face it folks, if these yahoos couldn't find financing during a pandemic, for a phase 3 fast track designated drug which "may" have been helpful for people suffering from COVID, they will never find it. Game over. Now just sell the shell and ride off into the sunset.
I have very few left. Finding a buyer and transaction costs would be way higher than it’s worth.
I have 2 people who want to sell a lot more than I have. Altitrade made a fake offer and never bought.
You should sell your shares them
NO ONE will buy this ticker. It's hard to clean "filth." Much easier to start from scratch. No news is good news. Why in the world would anyone buy a shell that was used for scamming people and have obligations to shareholders. Empty shell with obligations = bad deal.
Got it. Yes, it might be viable as a shell but am pretty sure the current company will never succeed, let alone trade again.
No matter, some entity will buy this ticker. Super clean for another company. Eventually, in my opinion. Happens all the time and is what is the deal in OTC.
Got shares, good deal.
I seriously doubt that. I believe they received the phase 3 fast track designation in 2007 and have not done squat. These guys are toast, IMHO.
One day this will trade again as some type of going concern. Then every shareholder might get back what was put into this b.s. ticker.
CRXM???
I believe your about a yr late on the borrow cheap money philosophy.
Better borrow some money now before there exists no cheap money for studies.
CRXM has this ticker and hasn't done anything with this at all. Makes no sense??
The people own this ticker must not be looking in the right place for the money to move this along.
In my opinion
CRXM???
I have some money in my pocket. A few bills and some loose change.It isn't a lot but considering the current value is .000001 it would seem like a fortune.
Anyone needs some shares? Buddy of mine has close to 1m he wants to dump.
On August 2, 2021, the Audit Committee approved the appointment of RAM Associates, LLP (“RAM Associates”) as our new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal years ending December 31, 2021 and 2020. RAM Associates has served as the auditor for Nostrum Laboratories, Inc. and its affiliates, which are subsidiaries of Nostrum Pharmaceuticals LLC, our largest shareholder, since 2008.
Clinicaltrials.com update:
https://clinicaltrials.gov/ct2/show/NCT02928094?term=generx&rank=1
Understanding refractory angina and the AFFIRM study:
https://www.myrefractoryangina.com/
Taxus Cardium Announces Name Change To Gene Biotherapeutics
January 10, 2018 PR-M01-18-NI-021
SAN DIEGO, Jan. 8, 2018 /PRNewswire/— Taxus Cardium Pharmaceuticals Group (Trading Symbol: CRXM) today announced plans to affect a name change from Taxus Cardium Pharmaceuticals Group Inc. to Gene Biotherapeutics Inc.
The name change reflects the Company's plan to exclusively focus on the late-stage clinical research and commercialization of gene-based biotherapeutics for niche markets in the oncology and cardiology spaces for patients with unmet medical needs. Gene Biotherapeutics is actively pursuing the acquisition of clinical development and commercialization rights to new and innovative, late-stage, DNA-based product opportunities focused on multiple forms of cancer to leverage the company's established and validated adenovector-based technology platform and deep experience in the clinical advancement and commercialization of gene therapy product candidates.
Previously, the Company established Angionetics Inc., an 85% majority-owned subsidiary, to lead Gene Biotherapeutics' cardiovascular clinical research and commercialization activities. Angionetics is currently focused on independent financings to support advancement of the FDA-cleared, Generx AFFIRM Phase 3 clinical study of patients with refractory angina (myocardial ischemia) due to advanced coronary artery disease. There are an estimated 1.0 million patients with refractory angina in the United States. Gene Biotherapeutics' plan to advance forward to establish Angionetics as an independent company remains unchanged. As previously reported, Gene Biotherapeutics expects to retain a substantial long-term equity investment in Angionetics following completion of the planned external financings. For more information about the Generx AFFIRM Phase 3 clinical study visit www.MyRefractoryAngina.com.
Angionetics is also considering the initiation of multiple Phase 2 clinical studies to evaluate the Generx angiogenic gene therapy product candidate as a treatment for patients with Cardiac Syndrome X (microvascular dysfunction) and certain forms of congestive heart failure, including ischemic cardiomyopathy.
Angionetics' Generx [Ad5FGF-4] is a first in class, disease altering, one-time administered, late-stage, angiogenic gene therapy product candidate which has been biologically engineered to enhance blood flow (perfusion) in ischemic regions of the heart by leveraging cardiac plasticity to promote the natural formation and growth of microvascular coronary structures (collateral vessels). This is achieved by stimulating and augmenting the heart's innate natural capacity to modulate the enlargement of pre-existing collateral arterioles (arteriogenesis), and to form new capillary vessels (angiogenesis) in select ischemic regions downstream from large coronary arteries.
Angionetics is being uniquely positioned to become a leading molecular interventional cardiology company, and is seeking to develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products focused on the biologic modulation of cardiac conductivity, contraction and angiogenic revascularization to address the global unmet medical needs of millions of patients with multiple forms of heart disease. Consistent with Angionetics' business strategy, the company is currently considering the acquisition of several early-stage gene therapy product candidates. To learn more about Angionetics visit www.angionetics.com.
As previously reported, Gene Biotherapeutics further plans to monetize its FDA-cleared, U.S.-patented, Excellagen, a highly-purified, aseptically-manufactured, fibrillar bovine collagen [2.6%] flowable dermal matrix for the treatment of diabetic neuropathic lower extremity ulcers, pressure and venous ulcers as well as other wound healing applications. Excellagen has demonstrated its medical utility as a delivery platform for stem cells, and also carries the potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes. Excellagen® has been designated as a skin substitute (bearing a unique product Q Code), in accordance with the standards established by the U.S. Centers for Medicare and Medicaid Services (CMS). For more information about Excellagen, visit https://www.youtube.com/watch?v=D2GYCYc_8JE.
As of December 31, 2017, approximately 14.3 million shares of Gene Biotherapeutics Common Stock were issued and outstanding, and approximately 4.6 million additional shares of Common Stock have been reserved for future issuance upon the conversion of the Series A Convertible Preferred Stock.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |